We're wondering whether Shire CEO Angus Russell and Novartis chief Joe Jimenez were separated at birth. Sure, the two companies are worlds apart, size-wise. But the two CEOs both see pharma's future--and the future of their own companies--as more customer-oriented and nimble, informed by strategies long used in the consumer-goods business.
Novartis CEO Joe Jimenez managed to impress the Wall Street crowd today with some solid numbers for the second quarter.
Novartis CEO Joe Jimenez has a new answer to his critics in Switzerland, where the drug giant's major layoff plans ignited a wave of protests against the company.
Novartis CEO Joe Jimenez says he chose to cut jobs "from a position of strength," rather than wait until company performance forced his hand.
If there's one thing that Novartis ($NVS) CEO Joe Jimenez likes to talk about, it's efficiency.
The idea of facing generic competition for a $5 billion blockbuster like Diovan would daunt almost any CEO. But Joe Jimenez (photo) says his experience hawking baby food and ketchup at Heinz made him
Maybe it's the rarefied Davos air or the long-range mountain views, but Novartis ($NVS) CEO Joe Jimenez is feeling optimistic about the post- Diovan future. After the Swiss drugmaker loses patent...
Don't accuse Novartis ($NVS) CEO Joe Jimenez (photo) of refusing to listen. After workers in Nyon, Switzerland, stopped work to protest their plant's closure, the company sat down to talk about other
Novartis ($NVS) CEO Joe Jimenez (photo) is no stranger to the executive Q&A; he's been chatted up by almost every big media outlet there is. However, every once in a while, he drops a bit of new
The good news for Novartis ($NVS): Workers in Nyon, Switzerland, have ended their strike. The not-so-good: If union leaders and employees think the drugmaker isn't negotiating in good faith, they'll